Dimerix Limited (ASX: DXB), a biopharmaceutical company with a Phase 3 clinical asset in kidney disease, today announces that the ACTION3 Phase 3 trial of DMX-200 in patients with focal segmental ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback